COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)

1. Porfidia, A, Valeriani, E, Pola, R, et al. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res 20202020; 196: 67–74.
Google Scholar | Crossref | Medline2. Bowles, L, Platton, S, Yartey, N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. New Engl J Med 2020; 383: 288–290.
Google Scholar | Crossref | Medline3. Wichmann, D, Sperhake, JP, Lütgehetmann, M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020; 173: 268–277.
Google Scholar | Crossref | Medline4. Klok, FA, Kruip, MJHA, van der Meer, NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191: 148–150.
Google Scholar | Crossref | Medline5. Middeldorp, S, Coppens, M, Haaps, TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020; 18: 1995–2002.
Google Scholar | Crossref | Medline6. Kubes, P, Suzuki, M, Granger, DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991; 88: 4651–4655.
Google Scholar | Crossref | Medline | ISI7. Chaturvedi, S, Brodsky, RA, McCrae, KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol 2019; 10: 449.
Google Scholar | Crossref | Medline8. Cugno, M, Meroni, PL, Gualtierotti, R, et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun 2021; 116: 102560.
Google Scholar | Crossref | Medline9. Leppkes, M, Knopf, J, Naschberger, E, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020; 58: 102925.
Google Scholar | Crossref | Medline10. Meng, H, Yalavarthi, S, Kanthi, Y, et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol 2017; 69: 655–667.In
Google Scholar | Crossref | Medline11. Varga, Z, Flammer, AJ, Steiger, P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417–1418.
Google Scholar | Crossref | Medline12. Ruiz-Ortega, M, Lorenzo, O, Rupérez, M, et al. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol 2001; 135: 123–137.
Google Scholar | Crossref13. Ahmetaj-Shala, B, Peacock, TP, Baillon, L, et al. Resistance of endothelial cells to SARS-CoV-2 infection in vitro. BioRxiv Immunology 2020. DOI: 10.1101/2020.11.08.372581.
Google Scholar | Crossref14. Corban, MT, Duarte-Garcia, A, McBane, RD, et al. Antiphospholipid syndrome. J Am Coll Cardiol 2017; 69: 2317–2330.
Google Scholar | Crossref | Medline15. Giardini, V, Carrer, A, Casati, M, et al. Increased sFLT‐1/PlGF ratio in COVID ‐19: a novel link to angiotensin II ‐mediated endothelial dysfunction. Am J Hematol 2020; 95. DOI: 10.1002/ajh.25882.
Google Scholar | Crossref | Medline16. Mortensen, SA, Sander, B, Jensen, RK, et al. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc Natl Acad Sci 2017; 114: 986–991.
Google Scholar | Crossref | Medline17. Yu, J, Yuan, X, Chen, H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020; 136: 2080–2089.
Google Scholar | Crossref | Medline18. Magro, C, Mulvey, JJ, Berlin, D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1–13.
Google Scholar | Crossref | Medline19. Rand, JH, Wu, XX, Wolgast, LR, et al. A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. Thromb Res 2017; 156: 119–125.
Google Scholar | Crossref | Medline20. Chaturvedi, S, Braunstein, EM, Yuan, X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 2020; 135: 239–251.
Google Scholar | Crossref | Medline21. Valenti, L, Griffini, S, Lamorte, G, et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun 2021; 117: 102595.
Google Scholar | Crossref | Medline22. Tang, N, Bai, H, Chen, X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–1099.
Google Scholar | Crossref | Medline23. Zuo, Y, Yalavarthi, S, Shi, H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020;5(11):e138999. DOI: 10.1172/jci.insight.138999.
Google Scholar | Crossref | Medline24. Skendros, P, Mitsios, A, Chrysanthopoulou, A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 2020; 130: 6151–6157.
Google Scholar | Crossref | Medline25. Sule, G, Kelley, WJ, Gockman, K, et al. Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by β2 integrin Mac‐1. Arthritis Rheumatol 2020; 72: 114–124.
Google Scholar | Crossref | Medline26. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
Google Scholar | Crossref | Medline27. Luo, XH, Zhu, Y, Mao, J, et al. T cell immunobiology and cytokine storm of COVID‐19. Scand J Immunol 2021; 93. DOI: 10.1111/sji.12989.
Google Scholar | Crossref | Medline28. Stouthard, JML, Levi, M, Hack, CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738–742.
Google Scholar | Crossref | Medline29. Devreese, KMJ, Linskens, EA, Benoit, D, et al. Antiphospholipid antibodies in patients with COVID‐19: A relevant observation? J Thromb Haemost 2020; 18: 2191–2201.
Google Scholar | Crossref | Medline30. Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
Google Scholar | Crossref | Medline | ISI31. Zhang, Y, Cao, W, Jiang, W, et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis 2020; 50: 580–586.
Google Scholar | Crossref | Medline32. Devreese, KMJ, Groot, PG, Laat, B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis. J Thromb Haemost 2020; 18: 2828–2839.
Google Scholar | Crossref | Medline33. Borghi, MO, Beltagy, A, Garrafa, E, et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 2020; 11: 584241.
Google Scholar | Crossref | Medline34. Tripodi, A, Chantarangkul, V, Clerici, M, et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115: 672–678.
Google Scholar | Crossref | Medline | ISI35. Xiao, M, Zhang, Y, Zhang, S, et al. Antiphospholipid antibodies in critically Ill patients with COVID‐19. Arthritis Rheumatol 2020; 72: 1998–2004.
Google Scholar | Crossref | Medline36. Gatto, M, Perricone, C, Tonello, M, et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol 2020; 38: 754–759.
Google Scholar | Medline37. Zuo, Y, Estes, SK, Ali, RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Trans Med 2020; 12: eabd3876.
Google Scholar | Crossref | Medline38. Wenzel, C, Stoiser, B, Locker, GJ, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 2002; 30: 763–770.
Google Scholar | Crossref | Medline | ISI39. Shi, H, Zuo, Y, Navaz, S, et al. Endothelial cell-activating antibodies in COVID-19. MedRxiv: 2021: 21250041. DOI: 10.1101/2021.01.18.21250041.
Google Scholar | Crossref40. Hasan Ali, O, Bomze, D, Risch, L, et al. Erratum to: severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies. Clin Infect Dis 2020; 73(9):1746.
Google Scholar | Crossref41. Spyropoulos, AC, Levy, JH, Ageno, W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. J Thromb Haemost 2020; 18: 1859–1865.
Google Scholar | Crossref | Medline42. Zambrano, LD, Ellington, S, Strid, P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1641–1647. DOI: 10.15585/mmwr.mm6944e3.
Google Scholar | Crossref | Medline43. Greinacher, A, Thiele, T, Warkentin, TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New Engl J Med 2021; 384: 2092–2101.
Google Scholar | Crossref | Medline44. Loarce-Martos, J, García-Fernández, A, López-Gutiérrez, F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 2020; 40: 2015–2021.
Google Scholar | Crossref | Medline45. Boyarsky, BJ, Ruddy, JA, Connolly, CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80: 1098–1099.
Google Scholar | Crossref46. Strakhan, M, Hurtado-Sbordoni, M, Galeas, N, et al. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol 20142014; 2014: 1–7.
Google Scholar47. Mastellos, DC, Pires da Silva, BGP, Fonseca, BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol 2020; 220: 108598.
Google Scholar | Crossref | Medline48. Vargas, A, Boivin, R, Cano, P, et al. Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma. Respir Res 2017; 18: 207.
Google Scholar | Crossref | Medline49. Ali, RA, Gandhi, AA, Meng, H, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun 2019; 10: 1916.
Google Scholar | Crossref |

留言 (0)

沒有登入
gif